News

Device lets Parkinson’s patients track their own motor symptoms

Stanford University researchers developed a simple, portable device that allows Parkinson’s disease patients to monitor their motor symptoms remotely, in real time, providing their doctors with updated information that can be used to guide treatment decisions. Patients tap alternating fingers for 30 seconds on the two-lever device, called KeyDuo, which…

Trial testing Parkinson’s disease-modifying therapy hits milestone

Herantis Pharma announced that its Phase 1b clinical trial evaluating the safety and preliminary efficacy of HER-096, a potential disease-modifying therapy for Parkinson’s disease, has hit a key milestone: All dosing regimens and follow-up clinic visits have been completed. Top-line results from the trial (NCT06659562, EUCT2024-512532-30-00) —…

OM1 expands real-world data to help advance Parkinson’s research

OM1 has expanded a real-world dataset of people with neurological conditions, including Parkinson’s disease, adding health records and clinical notes for 500,000 more people. “Expanding our neurology network to more than 3 million patients represents a pivotal milestone in enabling better outcomes for neurology patients,” Carl Marci, MD,…

MJFF, Seal Rock collaboration eyes LRRK2 gene-targeting therapies

Seal Rock Therapeutics has joined a Michael J. Fox Foundation (MJFF) initiative to develop therapies targeted at the LRRK2 gene for the treatment of Parkinson’s disease. The program, LRRK2 Investigative Therapeutics Exchange (LITE), brings together academic and industry collaborators to support preclinical and clinical development aimed…

Parkinson’s fall prevention program gets high marks from most users

Most people with Parkinson’s disease who’d experienced recurring falls found a personalized, home-based fall prevention program in Australia helpful for improving their safety and confidence. That’s according to a new assessment of the six-month program, dubbed Integrate, which was shown to reduce fall rates by nearly half among participants…

Disease-modifying Parkinson’s therapy found safe in volunteers

ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s disease, was found to be safe and well tolerated in a Phase 1 clinical trial involving healthy volunteers, according to developer Energenesis Biomedical. Unlike currently available treatments, ENERGI-F705PD aims to address the causes of Parkinson’s and not just its symptoms.